Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
For instance, the pembrolizumab approval only looked at NSCLC patients. Do you extrapolate noninferiority to all indications for pembrolizumab, nivolumab, and/or atezolizumab?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Warren Alpert Medical School of Brown University
Answered on
The only one of these agents I use in my Breast Oncology practice is pembrolizumab. I would be comfortable substituting SC for IV pembrolizumab if covered by insurance, but I have not yet had an instance where I have tried this.
Join for free or sign in to see the full answer